
|Articles|May 14, 2014
How BMS is Doing RBM (Risk-Based Monitoring)
Author(s)Guest Blogger
At this year’s Bio IT World Conference, Thomas Verish, Group Director of Data Operations Services at Bristol-Myers Squibb,
Advertisement
At this year’s Bio IT World Conference, Thomas Verish, Group Director of Data Operations Services at Bristol-Myers Squibb, elaborated on BMS’s risk-based monitoring (RBM) pilot, and how they are leveraging data, statistical analysis and personnel to execute RBM.
In this
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
What Kinds of Disruption are GLP-1s Expected to Face
2
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
3
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
4
The Evolving Relationship Between FDA and Biotech
5




